Respert—
My posts tend to be more aspirational and
Respert—
My posts tend to be more aspirational and critical of pharma business-as-usual, rather than grounded in any direct experience in the biotech or pharmaceutical worlds. Your thoughtful and detailed perspective about how things are likely to go down is as clear a narrative as I’ve ever heard with respect to Cytodyn’s future. And the idea that we “could/should hear something at virtually any moment”—Wow! At times Cytodyn has felt like an ordeal rather than investment. Yet it really feels like we are getting so very close to the end game. And the comment that “they need to come to us” jives with my feeling that we are negotiating from a position of strength. Any thoughts on a CVR as part of the eventual deal?
I think it was Kat who said—more or less—that getting leronlimab to Big Pharma would get the drug to patients much quicker than we could on our own. I suspect many feel that way. And if that’s true—and there are no shenanigans or slow-walking from the acquiring firm—then I think that is a trade-off well worth doing. Absolutely no doubts there!
My final thought comes from living in a decade in San Francisco in the 1980s. You couldn’t avoid the AIDS epidemic, the fear and mystery surrounding this novel disease as so much was unknown. It was a death sentence back then. I was going to art school at SF State, but worked for a contractor doing carpentry during summers and breaks. (A lesbian contractor, for the record. It is San Francisco after all!). One of our jobs was making and installing brightly-colored formica panels in the stairwell of an AIDS clinic in the Mission. Brighten the mood a bit. I recall lots of gaunt, sick men passing me on their way up the stairs for appointments.
I’m looking at Dr Jay’s CV right this moment. He interned and did his residency at Mount Zion Hospital in San Francisco from 1986 to 89. So, he choose to come out to SF and do his residency right when the AIDS epidemic was raging. Major props from where I sit. ACT-UP opened it’s SF chapter in 1988, and Dr Jay became CEO and Medical Director of Quest Clinical Research in 1989. Doing front-line research on HIV. At that time a commitment to medical care and research for HIV patients couldn’t be separated from the activist and political side of things. (Fauci didn’t change his tune on AIDS until 89). I give Lalezari so much credit for being in the trenches for so long. Basically from the beginning. And his MA was in English Lit from the University of Virginia! Pretty well-rounded guy.
The point being—if there is any CEO of cash-poor biotech company that might think outside the box in terms of business-as-usual… it would be Dr Jay. Your scenario of a partnership leading to a buyout looks quite reasonable to me. It looks like the surest and quickest way to approvals and getting leronlimab into the bodies of patients. While there are other potential paths forward, I don’t claim to have insight into how they might play out. Building out that marketing/regulatory/sales team—pipe dreams on my account. No signs of that getting underway, and no money to do it. I don’t mind being schooled when you are so clearly correct.
But if you lined up four CEOs against a wall and asked “which one of these is not like the others”…
—Sherlock/peace out—
22
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
Top 5 Most Recently Viewed Articles
DriveCentric Partners with Dealer Pay for Seamless Payment Integration DriveCentric is making waves in the automotive industry with its recent partnership with Dealer Pay. This collaboration aims to revolutionize how dealerships handle customer payments within their CRM systems. By integrating Dealer Pay's payment solutions into DriveCentric's platform, dealerships can...
Continue Reading
Concerns Surrounding Coty Inc. Pomerantz Law Firm is currently looking into claims related to Coty Inc. (NYSE: COTY), a significant player in the beauty industry. Investors who have stakes in Coty are encouraged to understand the implications of these developments and how they might affect their investments. Danielle Peyton at the Pomerantz Firm is available for inquiries...
Continue Reading
Transformative AI Tools for Leaders In today's fast-paced business world, leveraging advanced technology can greatly influence decision-making. Rossman Partners has launched a robust AI-driven advisory tool called Big Bet Leadership GPT. This cutting-edge solution is tailored to assist executives and entrepreneurs in navigating high-pressure scenarios, boosting their...
Continue Reading
Tesla's Remarkable Stock Performance Tesla Inc. (NASDAQ: TSLA) has proven time and again to be a formidable player, not only in the electric vehicle (EV) sector but also in the stock market. The company's stock has shown impressive gains, rising approximately 55.82% within a brief period. Over the past year, TSLA has seen significant growth of 45.02%, and year-to-date, it...
Continue Reading
Metagenomi's Class Action Lawsuit Overview Investors of Metagenomi Inc. (NASDAQ: MGX) need to be aware of a class action lawsuit that has been initiated, seeking accountability after critical revelations about the company's operations. This legal action revolves around securities purchased in the defined class period, putting pressure on the company's management to...
Continue Reading